FTC Vote On BMS-Celgene Acquisition Splits Over Drug Pricing

 
• By Brenda Sandburg

Divesting Celgene's psoriasis drug Otezla will remedy anticompetitive harm from acquisition, US Federal Trade Commission votes 3-2. Dissenting Democrat commissioners want broader review of pharma mergers.

WASHINGTON, DC - MAY 4: Federal Trade Commission Headquarters in downtown Washington, DC on May 4, 2015.

More from Compliance

More from Pink Sheet